Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Advanced Undifferentiated Pleomorphic Sarcoma (SiARa-UPS)
NCT05017103Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2021
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in undifferentiated pleomorphic sarcoma (UPS), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2021; status: terminated.
02
Drugs
sintilimab
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)
Beyond the preview
Go deeper on NCT05017103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017103.